First patient dosed in Phase 2 study of tipifarnib in advanced cancers with HRAS mutations
18 May 2015 | By Victoria White
The first patient has been dosed in the Phase 2 clinical trial of tipifarnib in patients with locally advanced tumours that carry HRAS mutations...